CRESEMBA Powder for concentrate for solution for infusion (2024)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
CRESEMBA 200 mg powder for concentrate for solution for infusion.
Qualitative and quantitative composition
Each vial contains 200 mg isavuconazole (as 372.6 mg isavuconazonium sulfate). For the full list of excipients, see section 6.1.
Pharmaceutical form
Powder for concentrate for solution for infusion. White to yellow powder.
Therapeutic indications
CRESEMBA is indicated in adults for the treatment of: invasive aspergillosis mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given ...
Posology and method of administration
Posology Early targeted therapy (pre-emptive or diagnostic-driven therapy) may be instituted pending confirmation of the disease from specific diagnostic tests. However, once these results become available, ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Co-administration with ketoconazole (see section 4.5). Co-administration with high-dose ritonavir (>200 mg every ...
Special warnings and precautions for use
Hypersensitivity Hypersensitivity to isavuconazole may result in adverse reactions that include: anaphylactic reaction, hypotension, respiratory failure, dyspnoea, drug eruption, pruritus, and rash (see ...
Interaction with other medicinal products and other forms of interaction
Potential of medicinal products to affect the pharmacokinetics of isavuconazole Isavuconazole is a substrate of CYP3A4 and CYP3A5 (see section 5.2). Co-administration of medicinal products which are inhibitors ...
Fertility, pregnancy and lactation
Pregnancy There are no data from the use of CRESEMBA in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. CRESEMBA must not ...
Effects on ability to drive and use machines
Isavuconazole has a moderate potential to influence the ability to drive and use machines. Patients should avoid driving or operating machinery if symptoms of confusional state, somnolence, syncope, and/or ...
Undesirable effects
Summary of the safety profile The most common treatment-related adverse reactions in adults were elevated liver chemistry tests (7.9%), nausea (7.4%), vomiting (5.5%), dyspnoea (3.2%), abdominal pain (2.7%), ...
Overdose
Symptoms Symptoms reported more frequently at supratherapeutic doses of CRESEMBA (equivalent to isavuconazole 600 mg/day) evaluated in a QT study than in the therapeutic dose group (equivalent to isavuconazole ...
Pharmacodynamic properties
<b>Pharmacotherapeutic group:</b> Antimycotics for systemic use, triazole- and tetrazole derivative <b>ATC code:</b> J02AC05 Mechanism of action Isavuconazole is the active moiety formed after oral or ...
Pharmacokinetic properties
Isavuconazonium sulfate is a water-soluble prodrug that can be administered as an intravenous infusion or orally as hard capsules. Following administration, isavuconazonium sulfate is rapidly hydrolysed ...
Preclinical safety data
In rats and rabbits, isavuconazole at systemic exposures below the therapeutic level were associated with dose-related increases in the incidence of skeletal anomalies (rudimentary supernumerary ribs) ...
List of excipients
Mannitol (E421) Sulfuric acid (for pH-adjustment)
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Shelf life
4 years. Chemical and physical in-use stability after reconstitution and dilution has been demonstrated for 24 hours at 2°C to 8°C, or 6 hours at room temperature. From a microbiological point of view, ...
Special precautions for storage
Store in a refrigerator (2°C to 8°C). For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Nature and contents of container
One 10 mL Type I glass vial with rubber stopper and an aluminum cap with plastic seal.
Special precautions for disposal and other handling
Reconstitution One vial of the powder for concentrate for solution for infusion should be reconstituted by addition of 5 mL water for injections to the vial. The reconstituted concentrate contains 40 mg ...
Marketing authorization holder
Basilea Pharmaceutica Deutschland GmbH, Marie-Curie-Strasse 8, 79539, Lörrach, Germany
Marketing authorization number(s)
EU/1/15/1036/001
Date of first authorization / renewal of the authorization
Date of first authorisation: 15 October 2015 Date of latest renewal: 13 August 2020
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
